Department of Hematology, Nasser Cancer Institute, Cairo, Egypt
Research Article
Prognostic Significance of Early Molecular Response in Patients Diagnosed with Chronic Myeloid Leukemia in Chronic Phase Treated with Nilotinib: A First-Line Therapy
Author(s): Mohammad Abdallah Shazly*, Mohamed Osman Azzazi, Mohamed Abdelmooti Mohamed Samra and Ahmed Youssri Elsaed
Background: Chronic Myeloid Leukemia (CML) is one of malignant hematologic disorders arises from hematopoietic stem
cells. BCR-ABL transcript levels on the international scale at 3 and 6 months are defined as indicators of the early efficacy of
first line TKI treatment.
Aim To investigate the impact of Early Molecular Response (EMR; BCR-ABL ≤ 10% on the International scale at 3 or 6
months) on outcome of the newly diagnosed CML in chronic phase treated with Nilotinib.
Patients and Methods: The study was enrolled from 2018 to 2020 at Nasser Institute for Research and Treatment. This is a
prospective cohort study done on 94 newly diagnosed CML cases in Chronic Phase.
Results: A statistically significant difference was detected between patients not achieved EMR with peripheral blasts ≥ 5%,
whe.. View more»